Epi-Now, a Beverly Hills-based startup that markets emergency allergy drug cabinets, has raised $9.2 million from investors, according to a securities filing.
The medical device firm raised $9,251,965 in securities sold to 72 investors, according to a July 30 filing with the U.S. Securities and Exchange Commission.
The company was cofounded in May 2017 by private equity veteran Steven Hartman, who billed it on his LinkedIn page as “a 21st century alternative to the EpiPen for the administration of emergency epinephrine.”
A You Tube video demonstrates an EpiNOW Allergy Emergency cabinet that can contain life-saving epinepherine, allergy and asthma medications.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- UPDATE: Brentwood-Based Forcyte Biotechnologies Targets $2M Raise
- Hypothermia Devices Raises $11M in Funding
- Emmaus Life Sciences Raises $12 Million in Debt Securities
- BioSig Tech Raises $4 Million in Securities Offering
- SeqOnce BioSciences Raises $1M
- Emmaus Life Sciences Raises $2.6 Million From Investors
- Alpha Source Raises $41M in Seed Round
- Trethera Corp. Raises $8M During Biotech Investor Round